|
Dedicated to understanding the health-related benefits of nutraceuticals, functional foods and natural health products (health food), CCARM’s mandate is two-fold: to perform research on natural health products, and to provide the results and related information to the relevant scientific community and to the general public. The research on various natural products is delivered through both basic science experimentation and clinical trials. This approach provides mechanistic information to better understand how the product works and the relevancy of this information to the human population. CCARM is supported by Agriculture & Agrifood Canada, St. Boniface General Hospital and the University of Manitoba. CCARM scientists have affiliations with the Faculties of Medicine, Pharmacy, Human Ecology, Dentistry and Agricultural and Food Sciences at the University of Manitoba and the Institute of Cardiovascular Sciences and the Division of Neurodegenerative Disease at the St. Boniface General Hospital Research Centre.
Partners:
St. Boniface General Hospital, University of Manitoba, Agriculture and Agri-food Canada.
Mandate:
- To investigate the health-related effects of functional foods and nutraceuticals
- To develop reliable, scientific, evidence-based information concerning FFN
Disease Targets:
- diabetes/obesity
- cardiovascular disease
- immune disorders
Laboratory Component:
Twelve research labs located on second floor of St. Boniface Research Centre occupied by 6 researchers from the University of Manitoba and 6 researchers from Agriculture and Agri-food Canada. Two open laboratories will house common equipment that will enable our researchers to take advantage of the latest state-of-the-art technologies. The focus of these labs will be to conduct non-human studies with animal and cell culture models of disease that will ascertain safety, tolerance, active constituents and mechanism of action. The R.O. Burrell Laboratory, a level 2 biohazard animal facility located within the St. Boniface Research Centre, is assisting the investigators to develop unique animal models capable of assessing the benefits of novel bioactive compounds.
Clinical Study Capacity: CCARM will be leading studies to investigate safety and efficacy of FFN in humans. To reach these objectives, space on the third floor of the Asper Clinical Research Institute has been developed for conducting studies involving human subjects through the assistance of CCARM-affiliated physicians. In addition, CCARM can assist with protocol development and provide consultation on regulatory issues.
|
